These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 34591069)

  • 21. Gastroenteropancreatic neuroendocrine tumors: current perspectives and future challenges.
    Garcia-Carbonero R
    Cancer Metastasis Rev; 2014 Mar; 33(1):343-4. PubMed ID: 24357057
    [No Abstract]   [Full Text] [Related]  

  • 22. Large-cell neuroendocrine cancer of the colon following rituximab-based lymphoma treatment.
    Freeman HJ; Kwan PW; Webber D
    Can J Gastroenterol; 2012 Jan; 26(1):12-3. PubMed ID: 22288066
    [No Abstract]   [Full Text] [Related]  

  • 23. Pathological incidence of duodenopancreatic neuroendocrine tumors in the Netherlands: a Pathologisch Anatomisch Landelijk Geautomatiseerd Archief study.
    Kuiper P; Verspaget HW; van Slooten HJ; Overbeek L; Biemond I; Lamers CB
    Pancreas; 2010 Nov; 39(8):1134-9. PubMed ID: 20871479
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pancreas neuroendocrine tumors - not so rare or benign.
    Pereira Pérez F
    Rev Esp Enferm Dig; 2016 Nov; 108(11):687-688. PubMed ID: 27756141
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Peritoneal Metastases from Gastroenteropancreatic Neuroendocrine Tumors.
    Frilling A; Clift AK
    Ann Surg Oncol; 2017 Nov; 24(12):3466-3468. PubMed ID: 28815440
    [No Abstract]   [Full Text] [Related]  

  • 26. Clinicopathologic features, incidence, and survival trends of gynecologic neuroendocrine tumors: a SEER database analysis.
    Gibbs J; Mei S; Economos K; Lee YC; Kanis MJ
    Am J Obstet Gynecol; 2019 Jul; 221(1):53.e1-53.e6. PubMed ID: 30849352
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epidemiology of gastroenteropancreatic neuroendocrine tumours.
    Fraenkel M; Kim MK; Faggiano A; Valk GD
    Best Pract Res Clin Gastroenterol; 2012 Dec; 26(6):691-703. PubMed ID: 23582913
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk of Primary Neuroendocrine Pancreatic Tumor After a First Primary Cancer: A US Population-Based Study.
    Kamath GR; Kim MK; Taioli E
    Pancreas; 2019 Feb; 48(2):161-168. PubMed ID: 30589832
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Localized high-grade gastroenteropancreatic neuroendocrine tumors: Defining prognostic and therapeutic factors for a disease of increasing clinical significance.
    Mosquera C; Koutlas NJ; Fitzgerald TL
    Eur J Surg Oncol; 2016 Oct; 42(10):1471-7. PubMed ID: 27528467
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incidence and survival trends for gastric neuroendocrine neoplasms: An analysis of 3523 patients in the SEER database.
    Cao LL; Lu J; Lin JX; Zheng CH; Li P; Xie JW; Wang JB; Chen QY; Lin M; Tu RH; Huang CM
    Eur J Surg Oncol; 2018 Oct; 44(10):1628-1633. PubMed ID: 29983275
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recurrence in Resected Gastroenteropancreatic Neuroendocrine Tumors.
    Singh S; Chan DL; Moody L; Liu N; Fischer HD; Austin PC; Segelov E
    JAMA Oncol; 2018 Apr; 4(4):583-585. PubMed ID: 29543939
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Population-level analysis of pancreatic neuroendocrine tumors 2 cm or less in size.
    Kuo EJ; Salem RR
    Ann Surg Oncol; 2013 Sep; 20(9):2815-21. PubMed ID: 23771245
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Neuroendocrine tumors of the stomach. Risk stratification and therapy].
    Klöppel G; Scherübl H
    Pathologe; 2010 May; 31(3):182-7. PubMed ID: 20306044
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Distribution, incidence, and prognosis in neuroendocrine tumors: a population based study from a cancer registry.
    Caldarella A; Crocetti E; Paci E
    Pathol Oncol Res; 2011 Sep; 17(3):759-63. PubMed ID: 21476126
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recent Advances in the Management of Typical and Atypical Lung Carcinoids.
    Prinzi N; Rossi RE; Proto C; Leuzzi G; Raimondi A; Torchio M; Milione M; Corti F; Colombo E; Prisciandaro M; Cascella T; Spreafico C; Beninato T; Coppa J; Lo Russo G; Di Bartolomeo M; de Braud F; Pusceddu S
    Clin Lung Cancer; 2021 May; 22(3):161-169. PubMed ID: 33618994
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of Therapy-Related Myeloid Neoplasms in Patients With Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy: A Systematic Review.
    Sonbol MB; Halfdanarson TR; Hilal T
    JAMA Oncol; 2020 Jul; 6(7):1086-1092. PubMed ID: 32297906
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Challenges in recognizing treatment-related neuroendocrine prostate cancer.
    Beltran H; Tagawa ST; Park K; MacDonald T; Milowsky MI; Mosquera JM; Rubin MA; Nanus DM
    J Clin Oncol; 2012 Dec; 30(36):e386-9. PubMed ID: 23169519
    [No Abstract]   [Full Text] [Related]  

  • 38. Paraneoplastic syndromes in neuroendocrine neoplasms of the head and neck: have they an impact on prognosis?
    Ferlito A; Shaha AR; Rinaldo A
    Acta Otolaryngol; 2001 Sep; 121(6):756-8. PubMed ID: 11678176
    [No Abstract]   [Full Text] [Related]  

  • 39. Advances in Systemic Therapy for Gastroenteropancreatic Neuroendocrine Malignancies.
    Halfdanarson TR; Strosberg JR
    Curr Clin Pharmacol; 2015; 10(4):305-10. PubMed ID: 26548907
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pattern and risk factors for distant metastases in gastrointestinal neuroendocrine neoplasms: a population-based study.
    Cai W; Tan Y; Ge W; Ding K; Hu H
    Cancer Med; 2018 Jun; 7(6):2699-2709. PubMed ID: 29733523
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.